Search research articles
Contact Us
Filters
Showing results (31-40 of 48) with videos related to
Page
of 5
Sort By:
Molecular and Cellular Biology
|
April 1, 1992
Nonmyristoylated Abl proteins transform a factor-dependent hematopoietic cell line
G Q Daley, R A Van Etten, P K Jackson, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
November 11, 1999
BCR-ABL and v-SRC tyrosine kinase oncoproteins support normal erythroid development in erythropoietin receptor-deficient progenitor cells
S Ghaffari, H Wu, M Gerlach, et al.
The Journal of Experimental Medicine
|
May 4, 1999
The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity
S Li, R L Ilaria, R P Million, et al.
Biotechnology and Bioengineering
|
August 5, 2000
Leukemia inhibitory factor (LIF) concentration modulates embryonic stem cell self-renewal and differentiation independently of proliferation
P W Zandstra, H V Le, G Q Daley, et al.
Science (New York, N.Y.)
|
July 11, 1986
The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene
Y Ben-Neriah, G Q Daley, A M Mes-Masson, et al.
Oncogene
|
June 23, 2001
Autocrine and paracrine effects of an ES-cell derived, BCR/ABL-transformed hematopoietic cell line that induces leukemia in mice
D G Peters, K M Klucher, R C Perlingeiro, et al.
Blood
|
February 27, 2001
Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia
D G Peters, R R Hoover, M J Gerlach, et al.
Oncogene
|
August 9, 2007
Quantitative monitoring by polymerase colony assay of known mutations resistant to ABL kinase inhibitors
V Nardi, T Raz, X Cao, et al.
Leukemia & Lymphoma
|
July 27, 2016
Inhibition of P210BCR/ABL Expression in K562 Cells by Electroporation with an Antisense Oligonucleotide
A S Taj, P Martiat, S Dhut, et al.
Leukemia
|
October 17, 2003
Treatment by design in leukemia, a meeting report, Philadelphia, Pennsylvania, December 2002
R A Larson, G Q Daley, C A Schiffer, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 48) with videos related to
Sort By:
Page
of 5
Molecular and Cellular Biology
|
April 1, 1992
Nonmyristoylated Abl proteins transform a factor-dependent hematopoietic cell line
G Q Daley, R A Van Etten, P K Jackson, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
November 11, 1999
BCR-ABL and v-SRC tyrosine kinase oncoproteins support normal erythroid development in erythropoietin receptor-deficient progenitor cells
S Ghaffari, H Wu, M Gerlach, et al.
The Journal of Experimental Medicine
|
May 4, 1999
The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity
S Li, R L Ilaria, R P Million, et al.
Biotechnology and Bioengineering
|
August 5, 2000
Leukemia inhibitory factor (LIF) concentration modulates embryonic stem cell self-renewal and differentiation independently of proliferation
P W Zandstra, H V Le, G Q Daley, et al.
Science (New York, N.Y.)
|
July 11, 1986
The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene
Y Ben-Neriah, G Q Daley, A M Mes-Masson, et al.
Oncogene
|
June 23, 2001
Autocrine and paracrine effects of an ES-cell derived, BCR/ABL-transformed hematopoietic cell line that induces leukemia in mice
D G Peters, K M Klucher, R C Perlingeiro, et al.
Blood
|
February 27, 2001
Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia
D G Peters, R R Hoover, M J Gerlach, et al.
Oncogene
|
August 9, 2007
Quantitative monitoring by polymerase colony assay of known mutations resistant to ABL kinase inhibitors
V Nardi, T Raz, X Cao, et al.
Leukemia & Lymphoma
|
July 27, 2016
Inhibition of P210BCR/ABL Expression in K562 Cells by Electroporation with an Antisense Oligonucleotide
A S Taj, P Martiat, S Dhut, et al.
Leukemia
|
October 17, 2003
Treatment by design in leukemia, a meeting report, Philadelphia, Pennsylvania, December 2002
R A Larson, G Q Daley, C A Schiffer, et al.
Page
of 5